Pneumocystis jirovecii with high probability detected in bronchoalveolar lavage fluid of chemotherapy-related interstitial pneumonia in patients with lymphoma using metagenomic next-generation sequencing technology

Table 1 Basic characteristics of the 15 patients with IP after chemotherapy

Patient ID	Sex	Age (years)	Histology	IPI score	Smoking	Basic lung disease	Chemotherapy	Cycles of chemotherapy before IP
P1	Male	33	DLBCL	2	Yes	No	R-CHOP R-CDOP	4
P2	Male	57	MCL	2	No	Bronchiectasis	R-CHOP CHOP	3
P3	Male	54	HL	1	Yes	No	ABVD	2
P4	Male	49	DLBCL	3	Yes	No	R-ECHOP R-CDOP	4
P5	Female	59	DLBCL	1	No	No	R-CHOP	3
P6	Female	62	DLBCL	1	No	No	CHOP R-CHOP	4
P7	Male	61	FL	2	No	No	R-CHOP	4
P8	Male	54	DLBCL	2	No	No	R-CDOP	5
P9	Female	57	DLBCL	3	No	No	R-CHOP R-CDOP R-ICE	14
P10	Male	64	DLBCL	3	Yes	No	ECHOP R-ECHOP	3
P11	Male	55	DLBCL	1	No	No	R-CDOP R-CHOP	8
P12	Male	30	ENKL	0	No	No	P-GIDE DHAP allo-HSCT Prednisone	20
P13	Female	59	PTCL-NOS	2	No	No	CDOP	1
P14	Male	58	DLBCL	3	No	No	R-EPOCH	2
P15	Male	62	DLBCL	2	No	No	RCDOP	2

IPI international prognostic index, DLBCL diffuse large B-cell lymphoma, MCL mantle cell lymphoma, HL Hodgkin’s lymphoma, FL follicular lymphoma, ENKL extranodal NK/T cell lymphoma, PTCL-NOS peripheral T-cell lymphoma-NOS, R rituximab, CHOP cyclophosphamide, epirubicin, vinorelbine, and dexamethasone/prednisone, CDOP cyclophosphamide, doxorubicin hydrochloride liposome, vinorelbine, and dexamethasone/prednison, ECHOP etoposide, cyclophosphamide, epirubicin, vinorelbine, and dexamethasone/prednison, EPOCH cyclophosphamide, epirubicin, vinorelbine, etoposide, and dexamethasone, ABVD doxorubicin hydrochloride liposome, bleomycin, vinorelbine, and dacarbazine, ICE ifosfamide, etoposide and cisplatin, P-GIDE pegaspargase plus gemcitabine, ifosfamide, dexamethasone, and etoposide, DHAP cisplatin, cytarabine and dexamethasone, allo-HSCT allogeneic hematopoietic stem cell transplantation

ISSN: 1750-9378